FDA Approves Zongertinib (Hernexeos): First Oral HER2-Targeted Therapy for Advanced NSCLC

In this episode, we break down the FDA’s historic approval of zongertinib (Hernexeos), the first oral HER2-targeted therapy for advanced non-small cell lung cancer (NSCLC) with HER2 mutations. This milestone offers patients and clinicians a long-awaited, convenient, and effective treatment option. You’ll learn: Why have HER2-mutated NSCLC patients had limited options until nowHow zongertinib works differently from intravenous HER2 therapiesKey results from the Beamion LUNG-1 clinical trial, i...